Developer docs
API playgroundTry for free, no card

Search company profiles

SolasCure

Full company profile

uuid0002g7d

Namestring
SolasCure
Legal namestring
Solascure Limited
Websiteurl
solascure.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SolasCure Limited is a Cambridge, United Kingdom-based clinical-stage biotechnology company founded in 2017 as a spin-off from German biotech BRAIN Biotech AG. The company is developing a single lead product, Aurase Wound Gel, an investigational biologic hydrogel containing tarumase (provisional International Nonproprietary Name), a recombinant fibrinolytic enzyme cloned from the saliva of medical maggots (Lucilia sericata). The enzyme works through a dual mechanism: it selectively debrides devitalised tissue (fibrin, collagen, elastin) while activating endogenous repair pathways via PAR2 receptors, with pH-dependent activity that self-deactivates as wounds heal. Phase II clinical trials (CLEANVLU2) demonstrated 22x faster debridement and 7x faster healing versus standard of care in chronic venous leg ulcers, and the FDA granted Fast Track Designation in 2025 for calciphylaxis ulcers.

The company is pre-commercial with no product revenue, having invested over USD 30 million to date across approximately GBP 26.3 million in equity financing (Series A GBP 15M in 2021 led by BRAIN Biotech AG and Seneca Partners; Series B GBP 10.9M in 2023 led by Seneca Partners with EVA Pharma, Jonathan Milner, and Wealth Club), plus non-dilutive grants from the European Innovation Council Accelerator (2023) and Innovate UK Biomedical Catalyst (GBP 405K, 2024). The intended revenue model is direct sales of the hydrogel to hospitals, specialist wound care clinics, community care settings, and GP surgeries, with potential licensing and partnership arrangements for commercialization. Pricing has not been disclosed.

SolasCure is advancing commercial readiness through a US Army Institute of Surgical Research collaboration on combat wound care (announced November 2024), selection for Innovate UK's Global Incubator Programme at the Texas Medical Center in Houston to support US market entry (announced June 2024), and a strengthened leadership bench featuring former Smith & Nephew Chief Medical Officer Andy Weymann as Chairman and CEO Lee Harle. The company operates clinical trials across the UK, US, and Hungary and has established an Expanded Access Program contact channel. Key awards include first place in EIT Health Catapult Biotech Category (2022), UK Life Sciences Innovator 2023, and the EIC Accelerator Grant (2023).

Short descriptiontext

SolasCure is a Cambridge, UK-based clinical-stage biotechnology company developing Aurase Wound Gel, an investigational biologic hydrogel containing the recombinant enzyme tarumase for enzymatic debridement and accelerated healing of chronic wounds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wound care therapeutics, enzymatic debridement, chronic wound healing, biologic wound gel, tissue repair therapy
Industry3 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Wound Care Biologics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical/Biologic Product Sales
TypeOne Time License
Description

SolasCure is developing Aurase Wound Gel as an investigational biologic product. Upon regulatory approval, the company will generate revenue through sales of the hydrogel product to healthcare systems, hospitals, wound care clinics, and community care providers. The company has invested over $30 million to date in development.

ift.tt
2Potential Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Following Phase II clinical trial success, the company is seeking partnership engagement and strategic partnerships for product commercialization, which may include licensing arrangements, co-development deals, or distribution partnerships.

solascure.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SolasCure is developing Aurase Wound Gel, an investigational biologic hydrogel containing tarumase — a recombinant fibrinolytic enzyme cloned from medical maggot saliva — for the treatment of chronic wounds. The product performs continuous enzymatic debridement while activating endogenous tissue repair pathways (PAR2 receptors) to accelerate healing of venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers. It is currently in Phase II clinical trials with FDA Fast Track Designation received for calciphylaxis ulcers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 22x faster debridement compared to standard of care (65% debridement vs 9% in control after 26 days, p=0.005)
+3 more records
Product overview1 text field

SolasCure is a single-product biotechnology company focused on developing Aurase Wound Gel as a mechanism-driven therapeutic for chronic wound healing. The product is a hydrogel formulation containing tarumase (provisional INN), a fibrinolytic enzyme derived from medical maggots. It works through a dual mechanism: continuous enzymatic debridement combined with activation of tissue repair pathways. The product has completed Phase II clinical trials for venous leg ulcers and received FDA Fast Track Designation for calciphylaxis ulcers. Key differentiators include pain-free application, temperature stability for community use, and compatibility with standard wound care workflows.

Product and service2 records
1Aurase Wound Gel
CategoryWound Care Biologics
Description

An investigational biologic hydrogel containing tarumase, a recombinant enzyme cloned from medical maggot (Lucilia sericata) saliva, designed for continuous enzymatic debridement and activation of endogenous PAR2 repair pathways. Targeted at chronic wound treatment including venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers, for use in hospitals, specialist wound care clinics, community care settings and home care.

2Expanded Access Program (EAP)
CategoryPatient Access Program
Description

Pre-approval access program enabling qualifying patients to receive Aurase Wound Gel prior to full regulatory approval and commercial launch. Contact via EAP@solascure.com.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1South Leicestershire Medical Group
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-17
Description

Clinical trial partnership for the CLEANVLU2 Phase II clinical trial being run in association with South Leicestershire Medical Group's community service.

solascure.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-06
Description

Research collaboration to evaluate Aurase Wound Gel for combat wound care. Two non-clinical development projects will assess the enzymatic debridement properties to reduce wound biofilm production and/or bioburden in prolonged field care scenarios, targeting Pseudomonas aeruginosa and MRSA strains.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-03
Description

Partnership through Innovate UK's Global Incubator Programme. TMC is the largest medical complex globally with over 1,760 life science companies. Programme includes customer discovery, mentorship, investor networking, and engagement with hospital administrators, procurement, and reimbursement professionals.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global wound care incumbent with advanced dressings, antimicrobial dressings, and AQUACEL product lines. Comparable as a broad portfolio competitor SolasCure will need to displace or partner with for hospital formulary access in chronic wound care.

TypeEmerging player
Description

Biologics company with wound care and osteoarthritis products including TheraSkin and other skin substitutes for chronic wounds. Comparable as a commercial-stage biologic wound therapy peer overlapping in diabetic foot ulcers and venous leg ulcers.

TypeBroad incumbent
Description

Spun-off 3M health care business with a major advanced wound care portfolio including Tegaderm and other dressings. Comparable as a global incumbent in chronic wound care procurement channels.

TypeBroad incumbent
Description

Swedish wound care specialist with Mepilex, Mepitel, and other advanced dressings. Comparable as a wound-focused incumbent competing in the same chronic wound care procurement channels and clinical settings SolasCure targets.

TypeOthers
Description

SolasCure's founding parent company and current strategic shareholder that originally cloned the tarumase enzyme. Relevant not as a competitor but as a corporate and IP relationship — BRAIN owns the Aurase and SolasCure trademarks and has a continuing board seat.

TypeDirect peer
Description

Commercial-stage regenerative medicine company selling skin substitutes and bioactive wound healing products (Apligraf, Dermagraft, PuraPly). Direct comparable as both companies market biologic/regenerative therapies for chronic wounds including venous leg ulcers, addressing the same clinician customer base.

TypeBroad incumbent
Description

Major wound and skin care company with Biatain and other advanced wound dressings. Relevant as a global wound care incumbent SolasCure will compete against in community care, hospital, and home care channels.

TypeBroad incumbent
Description

Global medical device leader with a large Advanced Wound Management franchise (including PICO and ACTICOAT). Highly relevant because SolasCure's Chairman Andy Weymann is former Smith & Nephew CMO, and Aurase would compete for formulary slots in the same wound care category Smith & Nephew dominates.

TypeDirect peer
Description

Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing, including venous leg ulcers and diabetic foot ulcers. Comparable as a regenerative biologic wound therapy commercializing in the same chronic wound indications SolasCure is targeting.

TypeBroad incumbent
Description

Medical device company with a wound care and regenerative tissue portfolio including Integra Dermal Regeneration Template. Comparable as it sells both advanced dressings and biologic/regenerative wound healing products into the same clinical audience.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SolasCure

Wound Care Biologicssolascure.com

SolasCure is a Cambridge, UK-based clinical-stage biotechnology company developing Aurase Wound Gel, an investigational biologic hydrogel containing the recombinant enzyme tarumase for enzymatic debridement and accelerated healing of chronic wounds.

What SolasCure does

SolasCure Limited is a Cambridge, United Kingdom-based clinical-stage biotechnology company founded in 2017 as a spin-off from German biotech BRAIN Biotech AG. The company is developing a single lead product, Aurase Wound Gel, an investigational biologic hydrogel containing tarumase (provisional International Nonproprietary Name), a recombinant fibrinolytic enzyme cloned from the saliva of medical maggots (Lucilia sericata). The enzyme works through a dual mechanism: it selectively debrides devitalised tissue (fibrin, collagen, elastin) while activating endogenous repair pathways via PAR2 receptors, with pH-dependent activity that self-deactivates as wounds heal. Phase II clinical trials (CLEANVLU2) demonstrated 22x faster debridement and 7x faster healing versus standard of care in chronic venous leg ulcers, and the FDA granted Fast Track Designation in 2025 for calciphylaxis ulcers.

The company is pre-commercial with no product revenue, having invested over USD 30 million to date across approximately GBP 26.3 million in equity financing (Series A GBP 15M in 2021 led by BRAIN Biotech AG and Seneca Partners; Series B GBP 10.9M in 2023 led by Seneca Partners with EVA Pharma, Jonathan Milner, and Wealth Club), plus non-dilutive grants from the European Innovation Council Accelerator (2023) and Innovate UK Biomedical Catalyst (GBP 405K, 2024). The intended revenue model is direct sales of the hydrogel to hospitals, specialist wound care clinics, community care settings, and GP surgeries, with potential licensing and partnership arrangements for commercialization. Pricing has not been disclosed.

SolasCure is advancing commercial readiness through a US Army Institute of Surgical Research collaboration on combat wound care (announced November 2024), selection for Innovate UK's Global Incubator Programme at the Texas Medical Center in Houston to support US market entry (announced June 2024), and a strengthened leadership bench featuring former Smith & Nephew Chief Medical Officer Andy Weymann as Chairman and CEO Lee Harle. The company operates clinical trials across the UK, US, and Hungary and has established an Expanded Access Program contact channel. Key awards include first place in EIT Health Catapult Biotech Category (2022), UK Life Sciences Innovator 2023, and the EIC Accelerator Grant (2023).

SolasCure firmographics

Firmographics
Name
SolasCure
Legal name
Solascure Limited
Website
https://solascure.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
SolasCure is a Cambridge, UK-based clinical-stage biotechnology company developing Aurase Wound Gel, an investigational biologic hydrogel containing the recombinant enzyme tarumase for enzymatic debridement and accelerated healing of chronic wounds.
Ownership category
akta.pro rank

SolasCure industry classification

Industry
Product category
Wound Care Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Wound care therapeutics
  • Enzymatic debridement
  • Chronic wound healing
  • Biologic wound gel
  • Tissue repair therapy

Where SolasCure is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

SolasCure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical/Biologic Product Sales: SolasCure is developing Aurase Wound Gel as an investigational biologic product. Upon regulatory approval, the company will generate revenue through sales of the hydrogel product to healthcare systems, hospitals, wound care clinics, and community care providers. The company has invested over $30 million to date in development.
  2. Potential Licensing and Partnership Revenue: Following Phase II clinical trial success, the company is seeking partnership engagement and strategic partnerships for product commercialization, which may include licensing arrangements, co-development deals, or distribution partnerships.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

SolasCure product offering

Product offering

Core offering

SolasCure is developing Aurase Wound Gel, an investigational biologic hydrogel containing tarumase — a recombinant fibrinolytic enzyme cloned from medical maggot saliva — for the treatment of chronic wounds. The product performs continuous enzymatic debridement while activating endogenous tissue repair pathways (PAR2 receptors) to accelerate healing of venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers. It is currently in Phase II clinical trials with FDA Fast Track Designation received for calciphylaxis ulcers.

Product overview

SolasCure is a single-product biotechnology company focused on developing Aurase Wound Gel as a mechanism-driven therapeutic for chronic wound healing. The product is a hydrogel formulation containing tarumase (provisional INN), a fibrinolytic enzyme derived from medical maggots. It works through a dual mechanism: continuous enzymatic debridement combined with activation of tissue repair pathways. The product has completed Phase II clinical trials for venous leg ulcers and received FDA Fast Track Designation for calciphylaxis ulcers. Key differentiators include pain-free application, temperature stability for community use, and compatibility with standard wound care workflows.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aurase Wound Gel An investigational biologic hydrogel containing tarumase, a recombinant enzyme cloned from medical maggot (Lucilia sericata) saliva, designed for continuous enzymatic debridement and activation of endogenous PAR2 repair pathways. Targeted at chronic wound treatment including venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers, for use in hospitals, specialist wound care clinics, community care settings and home care.
  • Expanded Access Program (EAP) Pre-approval access program enabling qualifying patients to receive Aurase Wound Gel prior to full regulatory approval and commercial launch. Contact via EAP@solascure.com.

Quantifiable outcome

  • 22x faster debridement compared to standard of care (65% debridement vs 9% in control after 26 days, p=0.005)
  • +3 more outcomes

Companies that use SolasCure

Customer profile

Segments3 records

Ideal customer profiles3 records

SolasCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SolasCure partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major.

  • South Leicestershire Medical GroupmajorStrategic or Co-development Partner · 17 March 2025Clinical trial partnership for the CLEANVLU2 Phase II clinical trial being run in association with South Leicestershire Medical Group's community service.
  • U.S. Army Institute of Surgical Research (USAISR)majorStrategic or Co-development Partner · 6 November 2024Research collaboration to evaluate Aurase Wound Gel for combat wound care. Two non-clinical development projects will assess the enzymatic debridement properties to reduce wound biofilm production and/or bioburden in prolonged field care scenarios, targeting Pseudomonas aeruginosa and MRSA strains.
  • Texas Medical Center (TMC)majorStrategic or Co-development Partner · 3 June 2024Partnership through Innovate UK's Global Incubator Programme. TMC is the largest medical complex globally with over 1,760 life science companies. Programme includes customer discovery, mentorship, investor networking, and engagement with hospital administrators, procurement, and reimbursement professionals.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

SolasCure competitors and assessment

Company assessment

Broad incumbents

  • Convatec: Global wound care incumbent with advanced dressings, antimicrobial dressings, and AQUACEL product lines. Comparable as a broad portfolio competitor SolasCure will need to displace or partner with for hospital formulary access in chronic wound care.
  • 3M Health Care (Solventum): Spun-off 3M health care business with a major advanced wound care portfolio including Tegaderm and other dressings. Comparable as a global incumbent in chronic wound care procurement channels.
  • Mölnlycke Health Care: Swedish wound care specialist with Mepilex, Mepitel, and other advanced dressings. Comparable as a wound-focused incumbent competing in the same chronic wound care procurement channels and clinical settings SolasCure targets.
  • Coloplast: Major wound and skin care company with Biatain and other advanced wound dressings. Relevant as a global wound care incumbent SolasCure will compete against in community care, hospital, and home care channels.
  • Smith & Nephew: Global medical device leader with a large Advanced Wound Management franchise (including PICO and ACTICOAT). Highly relevant because SolasCure's Chairman Andy Weymann is former Smith & Nephew CMO, and Aurase would compete for formulary slots in the same wound care category Smith & Nephew dominates.
  • Integra LifeSciences: Medical device company with a wound care and regenerative tissue portfolio including Integra Dermal Regeneration Template. Comparable as it sells both advanced dressings and biologic/regenerative wound healing products into the same clinical audience.

Emerging players

  • Bioventus: Biologics company with wound care and osteoarthritis products including TheraSkin and other skin substitutes for chronic wounds. Comparable as a commercial-stage biologic wound therapy peer overlapping in diabetic foot ulcers and venous leg ulcers.

Others

  • BRAIN Biotech AG: SolasCure's founding parent company and current strategic shareholder that originally cloned the tarumase enzyme. Relevant not as a competitor but as a corporate and IP relationship — BRAIN owns the Aurase and SolasCure trademarks and has a continuing board seat.

Direct peers

  • Organogenesis: Commercial-stage regenerative medicine company selling skin substitutes and bioactive wound healing products (Apligraf, Dermagraft, PuraPly). Direct comparable as both companies market biologic/regenerative therapies for chronic wounds including venous leg ulcers, addressing the same clinician customer base.
  • MiMedx: Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing, including venous leg ulcers and diabetic foot ulcers. Comparable as a regenerative biologic wound therapy commercializing in the same chronic wound indications SolasCure is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights3 records

Customer concentration

SolasCure social profiles

Digital presence

SolasCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SolasCure leadership team

Management profile

Number of profiles

Profiles7 records

SolasCure funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SolasCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SolasCure

What does SolasCure do?

SolasCure is developing Aurase Wound Gel, an investigational biologic hydrogel containing tarumase — a recombinant fibrinolytic enzyme cloned from medical maggot saliva — for the treatment of chronic wounds. The product performs continuous enzymatic debridement while activating endogenous tissue repair pathways (PAR2 receptors) to accelerate healing of venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers. It is currently in Phase II clinical trials with FDA Fast Track Designation received for calciphylaxis ulcers.

Is SolasCure a public or private company?

SolasCure is a private company. It is classified as venture growth investor backed and is currently operating.

When was SolasCure founded?

SolasCure was founded in 2017. It employs 11 to 50 people.

Where is SolasCure based?

SolasCure is headquartered in Cambridge, United Kingdom, in the Europe region.

How does SolasCure make money?

Two revenue lines are on record. Pharmaceutical/Biologic Product Sales are the primary driver. The others are potential Licensing and Partnership Revenue.

Who are SolasCure's main competitors?

Broad incumbents on record are Convatec, 3M Health Care (Solventum), Mölnlycke Health Care, Coloplast, Smith & Nephew and Integra LifeSciences. Bioventus is listed as an emerging player. BRAIN Biotech AG is listed as an others. Direct peers are Organogenesis and MiMedx.

Does SolasCure have an API?

No public API is recorded for SolasCure.

What industry is SolasCure in?

SolasCure's product category is Wound Care Biologics. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmaTimesSolasCure trial shows faster healing with Aurase Wound GelSolasCure has completed its second phase 2 clinical trial (CLEANVLU2) of Aurase Wound Gel for chronic venous leg ulcers, demonstrating substantially faster wound healing compared to standard of care. At higher concentrations of the active ingredient tarumase, the gel achieved 22 times faster debridement and seven times faster healing rates, reaching 65% debridement and 58% wound area reduction after 26 days versus 9% and 15% respectively in the control group. The results support a dual mechanism of action and will guide further development as the company seeks partnership engagement.PharmiWeb.comSolasCure Completes Phase II Clinical Trial, Demonstrating Accelerated Healing With Aurase Wound GelSolasCure Ltd announced the successful completion of its Phase II clinical trial CLEANVLU2 for Aurase Wound Gel, demonstrating that the product achieved 22 times faster debridement and 7 times faster wound healing compared to standard of care in patients with treatment-resistant venous leg ulcers. At higher concentrations of the active ingredient tarumase, the wound gel reached 65% debridement versus 9% in the control group after 26 days, while delivering a 58% wound area reduction versus 15% in controls. The results support advancement to the next development phase and validate the product's dual mechanism of action, which combines continuous enzymatic debridement with activation of tissue repair pathways.Business Wire BlogSolasCure Completes Phase II Clinical Trial, Demonstrating Accelerated Healing With Aurase Wound GelSolasCure announced the successful completion of its Phase II clinical trial CLEANVLU2 for Aurase Wound Gel, demonstrating 22 times faster debridement and 7 times faster healing compared to standard of care in patients with treatment-resistant venous leg ulcers. After 26 days, the gel achieved 65% debridement versus 9% in the control group and 58% wound area reduction versus 15% in the control group, while maintaining an excellent safety profile with no additional pain to patients. The results validate the product's dual mechanism of action—continuous enzymatic debridement combined with activation of tissue repair pathways—and support advancement to the next phase of development.IptonlineSolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound CareSolasCure has been awarded a £405,000 Biomedical Catalyst grant from Innovate UK to advance the clinical development of its investigational product, Aurase Wound Gel. The funding will support optimization of the gel's stability and release kinetics to prepare for future clinical trials targeting chronic wound treatment. This award complements recent European Innovation Council funding as the company aims to address significant unmet medical needs in wound care.LoomlySolasCure raises €12M in Series B financeSolasCure, an EIT Health-supported biotech, closed a €12M Series B round led by Seneca Partners and others. The Cambridge-based company completed its Phase 2a clinical trial for Aurase Wound Gel, an enzymatic debridement product for chronic wounds. The funding will support its Phase II development.PharmaTimesSolasCure announces pivotal financing round for hydrogelSolasCure has completed a £10.9 million Series B financing round led by Seneca Partners, with participation from EVA Pharma, Wealth Club, and BRAIN Biotech. The funds will support further Phase 2 efficacy studies for Aurase Wound Gel, a hydrogel therapy containing an enzyme cloned from medical maggots designed to accelerate wound debridement.FinSMEsSolasCure Closes GBP 10.9M Series B FundingCambridge-based biotechnology company SolasCure has closed a GBP 10.9 million Series B funding round led by Seneca Partners with participation from BRAIN Biotech AG, EVA Pharma, and other investors. The company plans to utilize the capital to advance its Aurase Wound Gel through further Phase II clinical trials for chronic wound treatment.FinSMEsSolasCure Raises UK£1.2M in FundingCambridge, UK-based biotech startup SolasCure raised £1.2m, with £733k via Seneca EIS Portfolio Service and £500k via Seneca Growth Capital VCT. The company plans to use the funds to further develop its wound cleaning product Aurase, a hydrogel containing an enzyme cloned from medical maggots.BusinessCloudWound-cleaning MedTech SolasCure raises Series ASolasCure raised £15 million in a Series A to develop its wound-cleaning product Aurase, a hydrogel with an enzyme cloned from medical maggots. The round was led by BRAIN Biotech, with Seneca Partners and others participating. The funding will support moving Aurase into clinical trials.UKTNCambridge biotech lands £15M for its innovative wound care solution - UKTNCambridge biotech SolasCure completed a £15 million Series A round led by BRAIN Biotech AG, with Seneca Partners and others participating. The funds will support development of Aurase, a hydrogel wound cleaning product using an enzyme cloned from medical maggots. The company plans to move into clinical trial stages.